Introduction: What they say
A study from the Global Research Laboratory, Seoul National University, Korea shows that “Overexpression of Atg5 in mice activates autophagy and extends lifespan.” This study was published, in the online journal “Nature communications”, by Prof. Jung YK, Pyo Jo and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy: Avermectin, the parent of anti-parasitic drug Ivermecitin, activates autophagy and extends lifespan via up regulation of ATG5
From research findings to therapeutic opportunity:
This study suggests, for the first time, that Avermectin, by increasing the expression of its target gene ATG5, it may: (1) enhance autophagy, (2) promote leanness; (3) increase insulin sensitivity; (4) improve motor function; and (5) alleviate ageing features.
Figure1. Avermectin functions as a longevity promoting agent. Avermecitin increases ATG5 expression and promotes leanness, insulin sensitivity, motor function and longevity.
[easy_payment currency=”USD”]
Thus, pharmacological formulations encompassing “Avermectin or its activators, either alone or in combination with other longevity-promoting drugs or compounds, may be used to increase the lifespan of an individual (Fig.1).
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $50#
For payment and purchase information, you may reach us at info@genomediscovery.org
# Research cooperation
References:
Web: http://genomediscovery.org or newbioideas.com/
To cite: Boominathan, L., Lifespan extension therapy: Avermectin, the parent of anti-parasitic drug Ivermecitin, activates autophagy and extends lifespan via up regulation of ATG5, 9/August/2017, 12.46 am
Courtesy: When you cite us, just drop us a line at info@genomediscovery.org